{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:55:48Z","timestamp":1761742548175},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1016\/j.det.2004.09.001","type":"journal-article","created":{"date-parts":[[2005,4,14]],"date-time":"2005-04-14T13:54:58Z","timestamp":1113486898000},"page":"313-322","source":"Crossref","is-referenced-by-count":10,"title":["Advances in Antiviral Therapy"],"prefix":"10.1016","volume":"23","author":[{"given":"Jashin J.","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie R.","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen K.","family":"Tyring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.det.2004.09.001_bib1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0733-8635(01)00003-1","article-title":"Herpes simplex viruses 1 and 2","volume":"20","author":"Yeung-Yue","year":"2002","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.det.2004.09.001_bib2","first-page":"511","article-title":"An overview of sexually transmitted diseases, part I","volume":"41","author":"Brown","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.det.2004.09.001_bib3","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/archinte.1995.00430150071008","article-title":"The incidence of herpes zoster","volume":"155","author":"Donohue","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.det.2004.09.001_bib4","first-page":"1147","article-title":"Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups","volume":"43","author":"Henle","year":"1969","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.det.2004.09.001_bib5","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1093\/infdis\/171.4.1002","article-title":"Detection of human cytomegalovirus DNA, RNA, and antibody in normal donor blood","volume":"171","author":"Zhang","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.det.2004.09.001_bib6","doi-asserted-by":"crossref","first-page":"126","DOI":"10.7326\/0003-4819-125-2-199607150-00009","article-title":"Advances in the management of AIDS-related cytomegalovirus retinitis","volume":"125","author":"Masur","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.det.2004.09.001_bib7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/infdis\/161.2.185","article-title":"Treatment of recurrent herpes simplex labialis with oral acyclovir","volume":"161","author":"Spruance","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.det.2004.09.001_bib8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0733-8635(05)70022-X","article-title":"Advances in antiviral therapy in dermatology","volume":"16","author":"Evans","year":"1998","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.det.2004.09.001_bib9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s10227-002-0140-3","article-title":"Valacyclovir in the treatment of herpes simplex, herpes zoster, and other viral infections","volume":"7","author":"Wu","year":"2003","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.det.2004.09.001_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa035144","article-title":"Once-daily valacyclovir to reduce the risk of transmission of genital herpes","volume":"350","author":"Corey","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.det.2004.09.001_bib11","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1128\/AAC.39.7.1546","article-title":"Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults","volume":"39","author":"Beutner","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.det.2004.09.001_bib12","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/archfami.9.9.863","article-title":"Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older","volume":"9","author":"Tyring","year":"2000","journal-title":"Arch Fam Med"},{"key":"10.1016\/j.det.2004.09.001_bib13","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1097\/00002030-200006160-00019","article-title":"Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group","volume":"14","author":"Romanowski","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.det.2004.09.001_bib14","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/bjo.85.5.576","article-title":"Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study","volume":"85","author":"Tyring","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.det.2004.09.001_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1081\/CNV-100000070","article-title":"A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients","volume":"19","author":"Tyring","year":"2001","journal-title":"Cancer Invest"},{"key":"10.1016\/j.det.2004.09.001_bib16","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1001\/jama.1997.03540410052030","article-title":"Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group","volume":"277","author":"Spruance","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.det.2004.09.001_bib17","first-page":"133","article-title":"Valganciclovir: new preparation. CMV retinitis: a simpler, oral treatment","volume":"12","year":"2003","journal-title":"Prescribe Int"},{"key":"10.1016\/j.det.2004.09.001_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0733-8635(02)00116-X","article-title":"Topical cidofovir for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial neoplasia, herpes simplex and its potential use in smallpox","volume":"21","author":"Toro","year":"2003","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.det.2004.09.001_bib19","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/clinids\/18.4.570","article-title":"Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC)","volume":"18","author":"Snoeck","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.det.2004.09.001_bib20","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1001\/archderm.134.9.1169","article-title":"Treatment of acyclovir-resistant, foscarnet-unresponsive HSV infection with topical cidofovir in a child with AIDS","volume":"134","author":"Lateef","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2004.09.001_bib21","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1086\/516542","article-title":"A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS","volume":"176","author":"Lalezari","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.det.2004.09.001_bib22","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0002-9394(02)01332-6","article-title":"Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS","volume":"133","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.det.2004.09.001_bib23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2165\/00002018-199716040-00003","article-title":"Minimising the dosage-limiting toxicities of foscarnet induction therapy","volume":"16","author":"Jayaweera","year":"1997","journal-title":"Drug Saf"},{"key":"10.1016\/j.det.2004.09.001_bib24","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1210\/jcem-72-5-1130","article-title":"Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism","volume":"72","author":"Jacobson","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.det.2004.09.001_bib25","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nm0402-386","article-title":"Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease","volume":"8","author":"Crute","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.det.2004.09.001_bib26","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm0402-392","article-title":"New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease","volume":"8","author":"Kleymann","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.det.2004.09.001_bib27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.mrrev.2003.06.013","article-title":"Genetic susceptibility to infection with human papillomavirus and development of cervical cancer in women in Brazil","volume":"544","author":"Savio de Araujo Souza","year":"2003","journal-title":"Mutat Res"},{"key":"10.1016\/j.det.2004.09.001_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1386-6532(00)00125-6","article-title":"Human papillomavirus and cancer: the epidemiological evidence","volume":"19","author":"Munoz","year":"2000","journal-title":"J Clin Virol"},{"key":"10.1016\/j.det.2004.09.001_bib29","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines 2002","volume":"51","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.det.2004.09.001_bib30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1396-0296.2004.04009.x","article-title":"Therapy of external anogenital warts and molluscum contagiosum: a literature review","volume":"17","author":"Ting","year":"2004","journal-title":"Dermatol Ther"},{"issue":"Suppl","key":"10.1016\/j.det.2004.09.001_bib31","doi-asserted-by":"crossref","first-page":"S212","DOI":"10.1067\/mjd.2002.126579","article-title":"Treatment of anogenital warts with imiquimod 5% cream followed by surgical excision of residual lesions","volume":"47","author":"Carrasco","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.det.2004.09.001_bib32","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1128\/AAC.46.10.3243-3248.2002","article-title":"Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled study","volume":"46","author":"Schacker","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.det.2004.09.001_bib33","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1128\/AAC.42.4.789","article-title":"Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts","volume":"42","author":"Beutner","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.det.2004.09.001_bib34","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0190-9622(98)70243-9","article-title":"Treatment of genital warts with an immune-response modifier (imiquimod)","volume":"38","author":"Beutner","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.det.2004.09.001_bib35","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1346-8138.1998.tb02429.x","article-title":"Management of female genital warts with an analog of imiquimod 2% in cream: a randomized, double-blind, placebo-controlled study","volume":"25","author":"Syed","year":"1998","journal-title":"J Dermatol"},{"key":"10.1016\/j.det.2004.09.001_bib36","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/00007435-200104000-00007","article-title":"Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day","volume":"28","author":"Fife","year":"2001","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.det.2004.09.001_bib37","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1086\/322007","article-title":"Application of a topically applied immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study","volume":"84","author":"Spruance","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.det.2004.09.001_bib38","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1086\/322593","article-title":"Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection","volume":"33","author":"Snoeck","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.det.2004.09.001_bib39","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00007435-200106000-00007","article-title":"Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons","volume":"28","author":"Matteelli","year":"2001","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.det.2004.09.001_bib40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0094-0143(21)00754-0","article-title":"Genital warts and molluscum contagiosum","volume":"11","author":"Margolis","year":"1984","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.det.2004.09.001_bib41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00007435-198107000-00012","article-title":"Molluscum contagiosum","volume":"8","author":"Brown","year":"1981","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.det.2004.09.001_bib42","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1001\/archderm.1997.03890440061010","article-title":"Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir","volume":"133","author":"Meadows","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2004.09.001_bib43","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/S0140-6736(99)01782-1","article-title":"Topical cidofovir for severe molluscum contagiosum","volume":"353","author":"Davies","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.det.2004.09.001_bib44","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1001\/archderm.136.8.983","article-title":"Topical cidofovir: a novel treatment for recalcitrant molluseum contagiosum in HIV infected children","volume":"136","author":"Toro","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2004.09.001_bib45","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1046\/j.1468-3083.2000.00184.x","article-title":"Topical cidofovir for severe cutaneous human papillomavirus and molluscum contagiosum infections in patients with HIV\/AIDS. A pilot study","volume":"14","author":"Calista","year":"2000","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2004.09.001_bib46","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0163-4453(99)90037-3","article-title":"A complete remission of recalcitrant molluscum contagiosum in an AIDS patient following highly active antiretroviral therapy (HAART)","volume":"38","author":"Cattelan","year":"1999","journal-title":"J Infect"},{"key":"10.1016\/j.det.2004.09.001_bib47","first-page":"211","article-title":"Resolution of disseminated molluscum contagiosum with highly active anti-retroviral therapy (HAART) in patients with AIDS","volume":"9","author":"Calista","year":"1999","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.det.2004.09.001_bib48","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00128071-200203010-00006","article-title":"Changing morbidity of cutaneous diseases in patients with HIV after the introduction of highly active antiretroviral therapy including a protease inhibitor","volume":"3","author":"Calista","year":"2002","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.det.2004.09.001_bib49","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jaad.2003.12.003","article-title":"Vaccines and immunotherapies for the prevention of infectious diseases having cutaneous manifestations","volume":"50","author":"Wu","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.det.2004.09.001_bib50","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.282.4.331","article-title":"Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials","volume":"282","author":"Corey","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.det.2004.09.001_bib51","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJMoa011915","article-title":"Glycoprotein-D-adjuvant vaccine to prevent genital herpes","volume":"347","author":"Stanberry","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.det.2004.09.001_bib52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/infdis\/175.1.16","article-title":"A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease","volume":"175","author":"Boursnell","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.det.2004.09.001_bib53","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/0264-410X(95)00259-4","article-title":"Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine","volume":"14","author":"McLean","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.det.2004.09.001_bib54","first-page":"235","article-title":"A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections","volume":"70","author":"Casanova","year":"2002","journal-title":"Cutis"},{"key":"10.1016\/j.det.2004.09.001_bib55","unstructured":"Reichman R., Balsley J., Carlin D., et al. Evaluation of the safety and immunogenicity of a recombinant HPV-11 L1 virus like particle vaccine in healthy adult volunteers. In: Gurley M., Carter C.D., Bounassif S., et al., editors. Proceedings of the 17th International Papillomavirus Conference. Charleston, SC, January 9\u201315, 1999"},{"key":"10.1016\/j.det.2004.09.001_bib56","unstructured":"Zhang L.F., Zhou J., Shao C., et al. A phase 1 trial of HPV 6 B virus like particles as immunotherapy for genital warts. International Papillomavirus Conference. Charleston, SC, January 9\u201315, 1999"},{"key":"10.1016\/j.det.2004.09.001_bib57","series-title":"International Papillomavirus Conference","article-title":"Chimeric papillomavirus virus-like particles induce antigen-specific therapeutic immunity against tumours expressing the HPV-16 E7 protein","author":"Silva","year":"1999"},{"key":"10.1016\/j.det.2004.09.001_bib58","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of a human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.det.2004.09.001_bib59","series-title":"A phase IIa study of a therapeutic vaccine for genital warts","author":"Lacey","year":"1997"},{"key":"10.1016\/j.det.2004.09.001_bib60","series-title":"The Jordan report. Accelerated development of vaccines, 2002","year":"2002"},{"key":"10.1016\/j.det.2004.09.001_bib61","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0140-6736(96)90674-1","article-title":"A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer","volume":"347","author":"Borysiewicz","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.det.2004.09.001_bib62","doi-asserted-by":"crossref","first-page":"8467","DOI":"10.1128\/JVI.71.11.8467-8474.1997","article-title":"Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA","volume":"71","author":"Jensen","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.det.2004.09.001_bib63","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00002371-199508000-00002","article-title":"Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor","volume":"18","author":"Ossevoort","year":"1995","journal-title":"J Immunother Emphasis Tumor Immunol"},{"key":"10.1016\/j.det.2004.09.001_bib64","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2741\/A356","article-title":"Papillomavirus vaccines","volume":"3","author":"Duggan-Keen","year":"1998","journal-title":"Front Biosci"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863504000877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863504000877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T18:06:19Z","timestamp":1625767579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863504000877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["S0733863504000877"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2004.09.001","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}